1. Pan American League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis
- Author
-
Fernández-Ávila, Daniel G., Bautista-Molano, Wilson, Brance, María Lorena, Ávila Pedretti, María Gabriela, Vargas, Rubén Burgos, Díaz Coto, José Francisco, Gutiérrez, Luis Arturo, Gutiérrez, Marwin, Ho, Enrique Giraldo, Ibáñez Vodnizza, Sebastián Eduardo, Jáuregui, Edwin, Ocampo, Vanessa, Palominos, Penélope Esther, Palleiro Rivero, Daniel Ruben, Quiceno, Guillermo Andrés, Sommerfleck, Fernando Andrés, Vega Espinoza, Luis Enrique, Hinojosa, Oscar Vega, Barrezueta, Claudia Vera, Corbacho, Inés, Cosentino, Vanesa Laura, Sariego, Annelise Goecke, Resende, Gustavo Gomes, Saldarriaga-Rivera, Lina María, Pacheco Tena, Cesar Francisco, Citera, Gustavo, Lozada, Carlos, Ranza, Roberto, Sampaio-Barros, Percival D., Schneeberger, Emilce, and Soriano, Enrique R.
- Abstract
ObjectivePsoriatic arthritis (PsA) is chronic disease that compromises multiple domains and might be associated with progressive joint damage, increased mortality, functional limitation, and considerably impaired quality of life. Our objective was to generate evidence-based recommendations on the management of PsA in Pan American League of Associations for Rheumatology (PANLAR) countries.MethodsWe used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)-ADOLOPMENT approach to adapt the 2019 recommendations of the European Alliance of Associations for Rheumatology. A working group consisting of rheumatologists from various countries in Latin America identified relevant topics for the treatment of PsA in the region. The methodology team updated the evidence and synthesized the information used to generate the final recommendations. These were then discussed and defined by a panel of 31 rheumatologists from 15 countries.ResultsTheses guidelines report 15 recommendations addressing therapeutic targets, use of antiinflammatory agents and corticosteroids, treatment with disease-modifying antirheumatic drugs (conventional synthetic, biologic, and targeted synthetic), therapeutic failure, optimization of biologic therapy, nonpharmacological interventions, assessment tools, and follow-up of patients with PsA.ConclusionHere we present a set of recommendations to guide decision making in the treatment of PsA in Latin America, based on the best evidence available, considering resources, medical expertise, and the patient’s values and preferences. The successful implementation of these recommendations should be based on clinical practice conditions, healthcare settings in each country, and a tailored evaluation of patients.
- Published
- 2024
- Full Text
- View/download PDF